05:18 AM EDT, 06/30/2025 (MT Newswires) -- Hutchmed ( HCM ) said Monday that the China National Medical Products Administration has approved its new drug application for the combination of Orpathys and Tagrisso to treat a certain type of lung cancer.

The approval covers locally advanced or metastatic epidermal growth factor receptor mutation-positive non-squamous non-small cell lung cancer with MET amplification after disease progression on EGFR tyrosine kinase inhibitor therapy.

The company said the approval triggers an $11 million milestone payment from AstraZeneca ( AZN ) , which markets both the drugs in China.